Cemiplimab plus chemotherapy versus chemotherapy alone in non-small cell lung cancer: Longer follow-up results from the phase III EMPOWER-Lung 3 trial

被引：0

作者：

Makharadze, T. ^{[1
]}

Gogishvili, M. ^{[2
]}

Melkadze, T. ^{[3
]}

Baramidze, A. ^{[3
]}

Giorgadze, D. ^{[4
]}

Penkov, K. D. ^{[5
]}

Laktionov, K. ^{[6
]}

Nemsadze, G. ^{[7
]}

Nechaeva, M. ^{[8
]}

Rozhkova, I. ^{[9
]}

Kalinka, E. ^{[10
]}

Li, S. ^{[11
]}

Li, Y. ^{[11
]}

Kaul, M. ^{[11
]}

Pouliot, J-F. ^{[11
]}

Seebach, F. ^{[11
]}

Lowy, I. ^{[11
]}

Gullo, G. ^{[11
]}

Rietschel, P. ^{[11
]}

机构：

[1] High Technol Hosp Medctr, Batumi, Georgia

[2] High Technol Med Ctr, Tbilisi, Georgia

[3] Acad F Todua Med Ctr, Tbilisi, Georgia

[4] David Tvildiani Med Univ, Tbilisi, Georgia

[5] Private Med Inst Euromedserv, St Petersburg, Russia

[6] Minist Hlth Russian Federat, Fed State Budgetary Inst, NN Blokhin Natl Med Res Ctr Oncol, Moscow, Russia

[7] Inst Clin Oncol, Tbilisi, Georgia

[8] Chelyabinsk Reg Clin Oncol Ctr, Chelyabinsk, Russia

[9] Kaluga Reg Clin Oncol Dispensary, Kaluga, Russia

[10] Polish Mothers Mem Hosp Res Inst, Lodz, Poland

[11] Regeneron Pharmaceut Inc, Tarrytown, NY USA

来源：

JOURNAL OF THORACIC ONCOLOGY | 2023年 / 18卷 / 04期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：S38 / S39

页数：2

共 50 条

[1] Cemiplimab plus chemotherapy versus chemotherapy in non-small cell lung cancer with PD-L1 ≥1%: EMPOWER-Lung 3 results
Baramidze, A.
Makharadze, T.
Gogishvili, M.
Melkadze, T.
Giorgadze, D.
Penkov, K. D.
Laktionov, K.
Nemsadze, G.
Nechaeva, M.
Rozhkova, I.
Kalinka, E.
McIntyre, D.
Kaul, M.
Quek, R. G. W.
Pouliot, J-F.
Seebach, F.
Gullo, G.
Rietschel, P.
ANNALS OF ONCOLOGY, 2023, 34
[2] Cemiplimab Plus Chemotherapy Versus Chemotherapy Alone in Advanced NSCLC: 2-Year Follow-Up From the Phase 3 EMPOWER-Lung 3 Part 2 Trial
Makharadze, Tamta
Gogishvili, Miranda
Melkadze, Tamar
Baramidze, Ana
Giorgadze, Davit
Penkov, Konstantin
Laktionov, Konstantin
Nemsadze, Gia
Nechaeva, Marina
Rozhkova, Irina
Kalinka, Ewa
Li, Siyu
Li, Yuntong
Kaul, Manika
Quek, Ruben G. W.
Poulio, Jean-Francois
Seebach, Frank
Lowy, Israel
Gullo, Giuseppe
Rietschel, Petra
JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (06) : 755 - 768
[3] Cemiplimab plus chemotherapy versus chemotherapy alone in non-small cell lung cancer with PD-L1 ≥ 1 %: A subgroup analysis from the EMPOWER-Lung 3 part 2 trial
Baramidze, Ana
Makharadze, Tamta
Gogishvili, Miranda
Melkadze, Tamar
Giorgadze, Davit
Penkov, Konstantin
Laktionov, Konstantin
Nemsadze, Gia
Nechaeva, Marina
Rozhkova, Irina
Kalinka, Ewa
McIntyre, Debra A. G.
Perez, Javier
Kaul, Manika
Quek, Ruben G. W.
Seebach, Frank
Rietschel, Petra
Pouliot, Jean-Francois
LUNG CANCER, 2024, 193
[4] Cemiplimab combined with chemotherapy versus chemotherapy in advanced non-small cell lung cancer: an updated EMPOWER-Lung 3 trial-based cost-effectiveness analysis
Zhu, Gaofeng
Cai, Hongfu
Zheng, Zhiwei
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2023, 15
[5] Cemiplimab plus chemotherapy versus chemotherapy alone in non-small cell lung cancer: a randomized, controlled, double-blind phase 3 trial
Gogishvili, Miranda
Melkadze, Tamar
Makharadze, Tamta
Giorgadze, Davit
Dvorkin, Mikhail
Penkov, Konstantin
Laktionov, Konstantin
Nemsadze, Gia
Nechaeva, Marina
Rozhkova, Irina
Kalinka, Ewa
Gessner, Christian
Moreno-Jaime, Brizio
Passalacqua, Rodolfo
Li, Siyu
McGuire, Kristina
Kaul, Manika
Paccaly, Anne
Quek, Ruben G. W.
Gao, Bo
Seebach, Frank
Weinreich, David M.
Yancopoulos, George D.
Lowy, Israel
Gullo, Giuseppe
Rietschel, Petra
NATURE MEDICINE, 2022, 28 (11) : 2374 - +
[6] Cemiplimab plus chemotherapy versus chemotherapy alone in non-small cell lung cancer: a randomized, controlled, double-blind phase 3 trial
Miranda Gogishvili
Tamar Melkadze
Tamta Makharadze
Davit Giorgadze
Mikhail Dvorkin
Konstantin Penkov
Konstantin Laktionov
Gia Nemsadze
Marina Nechaeva
Irina Rozhkova
Ewa Kalinka
Christian Gessner
Brizio Moreno-Jaime
Rodolfo Passalacqua
Siyu Li
Kristina McGuire
Manika Kaul
Anne Paccaly
Ruben G. W. Quek
Bo Gao
Frank Seebach
David M. Weinreich
George D. Yancopoulos
Israel Lowy
Giuseppe Gullo
Petra Rietschel
Nature Medicine, 2022, 28 : 2374 - 2380
[7] Cemiplimab Plus Chemotherapy Versus Chemotherapy Alone in Advanced NSCLC: 2-Year Follow-Up From the Phase 3 EMPOWER-Lung 3 Part 2 Trial (vol 18, pg 755, 2023)
Mao, W.
Chen, R.
Zhang, J.
Zheng, M.
JOURNAL OF THORACIC ONCOLOGY, 2025, 20 (01) : 119 - 121
[8] Quality of life with cemiplimab plus chemotherapy for first-line treatment of advanced non-small cell lung cancer: Patient-reported outcomes from phase 3 EMPOWER-Lung 3
Makharadze, Tamta
Quek, Ruben G. W.
Melkadze, Tamar
Gogishvili, Miranda
Ivanescu, Cristina
Giorgadze, Davit
Dvorkin, Mikhail
Penkov, Konstantin
Laktionov, Konstantin
Nemsadze, Gia
Nechaeva, Marina
Rozhkova, Irina
Kalinka, Ewa
Gessner, Christian
Moreno-Jaime, Brizio
Passalacqua, Rodolfo
Konidaris, Gerasimos
Rietschel, Petra
Gullo, Giuseppe
CANCER, 2023, 129 (14) : 2256 - 2265
[9] A Phase 2/3 Study of Fianlimab, Cemiplimab, plus Chemotherapy Versus Cemiplimab plus Chemotherapy in First-Line Advanced Non-Small Cell Lung Cancer
Gabrail, Nashat
Faulkner, Neil
Nair, Santosh
Ibrahim, Emad
Brungs, Daniel
Dreisbach, Luke
Kunta, Gopal
Mani, Jayakumar
Ghattas, Maria
Li, Siyu
Salvati, Mark
Lowy, Israel
Hiley, Tara
Fury, Matthew G.
Paoluzzi, Luca
JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (07) : E39 - E39
[10] First-line cemiplimab for locally advanced non-small cell lung cancer: Updated subgroup analyses from EMPOWER-Lung 1 and EMPOWER-Lung 3
Kalinka, E.
Bondarenko, I.
Gogishvili, M.
Melkadze, T.
Baramidze, A.
Sezer, A.
Makharadze, T.
Kilickap, S.
Gumus, M.
Penkov, K. D.
Giorgadze, D.
Ozguroglu, M.
He, X.
Pouliot, J-F.
Seebach, F.
Lowy, I.
Gullo, G.
Rietschel, P.
JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (04) : S106 - S106

← 1 2 3 4 5 →